Celldex Therapeutics | CLDX

Celldex Therapeutics traded at $22.70 this Friday July 1st, decreasing $4.26 or 15.80 percent since the previous trading session. Looking back, over the last four weeks, Celldex Therapeutics lost 0.96 percent. Over the last 12 months, its price fell by 32.94 percent. Looking ahead, we forecast Celldex Therapeutics to be priced at 22.08 by the end of this quarter and at 20.34 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 153.80 0.64 0.42% 33.54%
Agenus 1.96 0.02 1.03% -64.49%
Applied Genetic Technologies 0.78 0.01 1.31% -81.07%
Amgen 245.55 2.25 0.92% -1.27%
Aptinyx Inc 0.55 -0.01 -1.42% -80.50%
Biocept 0.94 -0.0001 -0.01% -77.67%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Celldex Therapeutics 22.70 -4.26 -15.80% -32.94%
CytrRx Corporation 0.10 0.01 7.19% -90.00%
Glaxosmithkline 43.75 0.22 0.51% 8.27%
Immunogen 4.61 0.11 2.44% -28.30%
Merrimack Pharmaceuticals 5.83 -0.12 -2.02% -7.46%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Lumos Pharma Inc. 7.69 -0.01 -0.13% -24.61%
Northwest Biotherapeutics 0.64 0.01 0.81% -56.65%
Pfizer 52.31 -0.12 -0.23% 31.66%
Rigel Pharmaceuticals 1.25 0.12 10.62% -71.66%
Roche Holding 319.35 -3.25 -1.01% -9.66%
Seattle Genetics 180.11 3.17 1.79% 14.52%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and development of CDX-015, CDX-1140 and CDX-527. CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, has completed a Phase Ia study in healthy subjects. CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, is being studied in a Phase I study. CDX-527 is the first candidate from Celldex's bispecific antibody platform. CDX-527 is a bispecific antibody that uses the Company's anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, and Company has initiated a Phase I study in advanced solid tumors.